Read the full article on Oncology Data Advisor:

https://oncdata.com/oncology-unfiltered-financial-toxicity

In this episode of Oncology Unfiltered, Melissa Cutrona, Co-Founder and General Manager of i3 Health and Oncology Data Advisor, and Matthew Hadfield, DO, Oncology Data Advisor Editor in Chief, explore how financial and geographic toxicities in oncology are, in reality, clinical toxicities. If a patient can’t afford to fill the prescription, is it really a treatment option?

They discuss what financial toxicity truly means—far beyond drug prices—covering travel, parking, time off work, and the hidden costs of tests and therapies. Dr. Hadfield shares real-world examples of patients turning down innovative treatments and clinical trials because they can’t afford the logistical burden, and explains how geography and income create a two-tiered system of cancer care.

The conversation examines how financial and geographic barriers distort shared decision making, limit participation in clinical trials, and skew our understanding of real-world efficacy. They also highlight the role of institutions, policymakers, and pharma in improving access, and why oncologists must reconsider ordering patterns, testing habits, and how they counsel patients about the full “cost” of care.

Thank you for watching Oncology Unfiltered. Check out our playlist and stay tuned for next month’s topic, “Molecular Testing Chaos: Are We Over-Testing, Under-Testing, or Testing the Wrong Things at the Wrong Time?”

Psoriatic arthritis management is evolving fast, but bridging the gap between clinical evidence and patient experience remains the ultimate challenge. When multidisciplinary teams and patients truly sync, care transforms.

i3 Health recently convened a Multidisciplinary Task Force to discuss early screening, comorbidities, and therapeutic optimization. In this exclusive follow-up interview, we sit down with Archie Franklin, MBA—a veteran PsA patient and Task Force moderator—to go beyond the data. Listen now to hear a unique, dual-perspective look at the changing treatment landscape, sharing candid reflections on how clinicians can bridge communication gaps and practically elevate outcomes for every patient.

Click the link to view the Task Force and claim your free CME/NCPD/CPE credit: https://bit.ly/4h5NSKb

Effective schizophrenia management requires a holistic, patient-centered approach tailored to the individual’s unique needs. This final module focuses on integrating evidence-based strategies with shared decision-making to foster recovery. If you missed any previous parts of this series, be sure to listen to Modules 1 through 3 to gain a comprehensive update on the latest research and treatment landscape.

Note: This podcast expires on 2/17. Click the link below to claim your CME/NCPD/CPE credit.

https://bit.ly/4oflWWZ

Cognitive impairment is a core feature of schizophrenia that contributes heavily to long-term disability. In Module 3, discover current and emerging pharmacologic treatments designed to target cognitive symptoms, alongside psychosocial and lifestyle interventions that enhance functioning. To complete the series, continue to Module 4 for a deep dive into applying these advances to patient-centered care.

Note: This podcast expires on 2/17. Click the link below to claim your CME/NCPD/CPE credit.

https://bit.ly/47fkz4p

Adherence to oral antipsychotics is frequently disrupted by complex dosing schedules and side effects. This module examines the clinical benefits of long-acting injectables (LAIs), including steadier blood concentrations and improved patient tolerance. Learn how the latest LAI formulations can transform treatment adherence and long-term stability. After listening, be sure to move on to Module 3 to learn about emerging treatments for cognitive symptoms.

Note: This podcast expires on 2/17. Click the link below to claim your CME/NCPD/CPE credit.

https://bit.ly/436dYa5

Schizophrenia remains a complex challenge that significantly impacts life expectancy and daily functioning. While dopamine-blocking agents have long been the standard of care, their limitations often leave patients with persistent symptoms. In this module, Dr. Christoph U. Correll explores the shortcomings of current therapies and discusses the latest efforts to optimize treatment strategies. Once you have completed this session, continue your learning journey by tuning into Module 2 to explore advances in long-acting injectables.

Note: This podcast expires on 2/17. Click the link below to claim your CME/NCPD/CPE credit.

https://bit.ly/432ICln

The treatment landscape for melanoma continues to evolve at a rapid pace, with new clinical trial data and therapeutic modalities refining how clinicians approach both early-stage and advanced disease. Michael A. Davies, MD, PhD, Professor and Chairman of the Department of Melanoma Medical Oncology at the University of Texas MD Anderson Cancer Center, recently chaired i3 Health’s CME/NCPD/AAPA activity, "Melanoma in Minutes: Evidence-Driven Care for Improved Patient Outcomes." With numerous new developments in melanoma treatment over recent months, Dr. Davies sat down again to share these critical updates that are impacting practice. After the interview, stay tuned to hear module 2 of the full podcast activity.

Click the link to complete module 2 and claim your free credit: bit.ly/44yO9RB

The treatment landscape for melanoma continues to evolve at a rapid pace, with new clinical trial data and therapeutic modalities refining how clinicians approach both early-stage and advanced disease. Michael A. Davies, MD, PhD, Professor and Chairman of the Department of Melanoma Medical Oncology at the University of Texas MD Anderson Cancer Center, recently chaired i3 Health’s CME/NCPD/AAPA activity, "Melanoma in Minutes: Evidence-Driven Care for Improved Patient Outcomes." With numerous new developments in melanoma treatment over recent months, Dr. Davies sat down again to share these critical updates that are impacting practice. After the interview, stay tuned to hear module 1 of the full podcast activity.

Click the link to complete module 1 and claim your free credit: bit.ly/4iYmYD2

Ready to close the gap in HER2-mutant NSCLC care? Join Memorial Sloan Kettering experts Helena A. Yu, MD, and Maria Arcila, MD, for a live webinar on optimizing HER2 testing and integrating the latest targeted therapies into your practice. They’ll walk through how to improve detection and ensure your patients are getting the most effective, up-to-date treatments available.

You can catch the live session on either of these dates:

Wednesday, January 8 at 5:00 pm ET: https://bit.ly/4iZxnA0

Monday, January 26 at 5:00 pm ET: https://bit.ly/4qALw9J

Join Lauren M. Madigan, MD, Associate Professor of Dermatology at the University of Utah, for a sneak peek at our upcoming live webinar, Beyond the Skin: Uncovering Systemic Mastocytosis (SM) in Dermatology Practice. In this short interview, Dr. Madigan shares practical insights on why SM is so often diagnosed late, how skin findings can be a key clue to recognition, and what’s new in the rapidly evolving world of targeted therapies.

The webinar will be offered on two dates. Click the links to register for the date that fits your schedule best!

Tuesday, January 13 at 5:00 pm ET - bit.ly/4p7HRil

Monday, February 2 at 7:00 pm ET - bit.ly/495gnEd